These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25679114)

  • 1. Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.
    Bruncko M; Wang L; Sheppard GS; Phillips DC; Tahir SK; Xue J; Erickson S; Fidanze S; Fry E; Hasvold L; Jenkins GJ; Jin S; Judge RA; Kovar PJ; Madar D; Nimmer P; Park C; Petros AM; Rosenberg SH; Smith ML; Song X; Sun C; Tao ZF; Wang X; Xiao Y; Zhang H; Tse C; Leverson JD; Elmore SW; Souers AJ
    J Med Chem; 2015 Mar; 58(5):2180-94. PubMed ID: 25679114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo design, synthesis and evaluation of benzylpiperazine derivatives as highly selective binders of Mcl-1.
    Ding X; Li Y; Lv L; Zhou M; Han L; Zhang Z; Ba Q; Li J; Wang H; Liu H; Wang R
    ChemMedChem; 2013 Dec; 8(12):1986-2014. PubMed ID: 24124106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Mcl-1/Bcl-2 dual inhibitors created by the structure-based hybridization of drug-divided building blocks and a fragment deconstructed from a known two-face BH3 mimetic.
    Zhang Z; Su P; Li X; Song T; Chai G; Yu X; Zhang K
    Arch Pharm (Weinheim); 2015 Feb; 348(2):89-99. PubMed ID: 25641608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.
    Fan F; Tonon G; Bashari MH; Vallet S; Antonini E; Goldschmidt H; Schulze-Bergkamen H; Opferman JT; Sattler M; Anderson KC; Jäger D; Podar K
    Cancer Lett; 2014 Feb; 343(2):286-94. PubMed ID: 24120758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of selective Mcl-1 inhibitors via structure-based design and structure-activity relationship analysis.
    He N; Liu P; Wang Z; Guo Z; Yan X; Chen H; Zhang Z
    Biochem Biophys Res Commun; 2019 May; 512(4):921-926. PubMed ID: 30928099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and in Vivo Evaluation of Macrocyclic Mcl-1 Inhibitors Featuring an α-Hydroxy Phenylacetic Acid Pharmacophore or Bioisostere.
    Rescourio G; Gonzalez AZ; Jabri S; Belmontes B; Moody G; Whittington D; Huang X; Caenepeel S; Cardozo M; Cheng AC; Chow D; Dou H; Jones A; Kelly RC; Li Y; Lizarzaburu M; Lo MC; Mallari R; Meleza C; Rew Y; Simonovich S; Sun D; Turcotte S; Yan X; Wong SG; Yanez E; Zancanella M; Houze J; Medina JC; Hughes PE; Brown SP
    J Med Chem; 2019 Nov; 62(22):10258-10271. PubMed ID: 31736296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design.
    Friberg A; Vigil D; Zhao B; Daniels RN; Burke JP; Garcia-Barrantes PM; Camper D; Chauder BA; Lee T; Olejniczak ET; Fesik SW
    J Med Chem; 2013 Jan; 56(1):15-30. PubMed ID: 23244564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors.
    Liu L; Liu R; Yang X; Hou X; Fang H
    Eur J Med Chem; 2020 Apr; 191():112142. PubMed ID: 32088497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-Phenyl-1H-indole derivatives as a new class of Bcl-2/Mcl-1 dual inhibitors: Design, synthesis, and preliminary biological evaluation.
    Xu G; Liu T; Zhou Y; Yang X; Fang H
    Bioorg Med Chem; 2017 Oct; 25(20):5548-5556. PubMed ID: 28866374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
    Wan Y; Wang J; Sun F; Chen M; Hou X; Fang H
    Bioorg Med Chem; 2015 Dec; 23(24):7685-93. PubMed ID: 26620718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a Copper-Based Mcl-1 Inhibitor as an Effective Antitumor Agent.
    Lu X; Liu YC; Orvig C; Liang H; Chen ZF
    J Med Chem; 2020 Sep; 63(17):9154-9167. PubMed ID: 32794745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
    Tron AE; Belmonte MA; Adam A; Aquila BM; Boise LH; Chiarparin E; Cidado J; Embrey KJ; Gangl E; Gibbons FD; Gregory GP; Hargreaves D; Hendricks JA; Johannes JW; Johnstone RW; Kazmirski SL; Kettle JG; Lamb ML; Matulis SM; Nooka AK; Packer MJ; Peng B; Rawlins PB; Robbins DW; Schuller AG; Su N; Yang W; Ye Q; Zheng X; Secrist JP; Clark EA; Wilson DM; Fawell SE; Hird AW
    Nat Commun; 2018 Dec; 9(1):5341. PubMed ID: 30559424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
    Niu Q; Deng H; Zhang Z; Xu Q; Luan S; Huang M; Liu D; Zhao L
    Bioorg Med Chem Lett; 2021 Sep; 47():128215. PubMed ID: 34153472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel indazole-acylsulfonamide hybrids as selective Mcl-1 inhibitors.
    Wan Y; Li Y; Yan C; Wen J; Tang Z
    Bioorg Chem; 2020 Nov; 104():104217. PubMed ID: 32911192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.
    Jorda R; Navrátilová J; Hušková Z; Schütznerová E; Cankař P; Strnad M; Kryštof V
    Chem Biol Drug Des; 2014 Oct; 84(4):402-8. PubMed ID: 24803299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein.
    Petros AM; Swann SL; Song D; Swinger K; Park C; Zhang H; Wendt MD; Kunzer AR; Souers AJ; Sun C
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1484-8. PubMed ID: 24582986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
    Lee T; Christov PP; Shaw S; Tarr JC; Zhao B; Veerasamy N; Jeon KO; Mills JJ; Bian Z; Sensintaffar JL; Arnold AL; Fogarty SA; Perry E; Ramsey HE; Cook RS; Hollingshead M; Davis Millin M; Lee KM; Koss B; Budhraja A; Opferman JT; Kim K; Arteaga CL; Moore WJ; Olejniczak ET; Savona MR; Fesik SW
    J Med Chem; 2019 Apr; 62(8):3971-3988. PubMed ID: 30929420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design, synthesis, and evaluation of Bcl-2/Mcl-1 dual inhibitors.
    Zhu J; Wang Z; Guo Z; Zhang X; Song T; Guo Y; Ji T; Zhang Z
    Arch Pharm (Weinheim); 2020 May; 353(5):e2000005. PubMed ID: 32175625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.
    Lee T; Bian Z; Zhao B; Hogdal LJ; Sensintaffar JL; Goodwin CM; Belmar J; Shaw S; Tarr JC; Veerasamy N; Matulis SM; Koss B; Fischer MA; Arnold AL; Camper DV; Browning CF; Rossanese OW; Budhraja A; Opferman J; Boise LH; Savona MR; Letai A; Olejniczak ET; Fesik SW
    FEBS Lett; 2017 Jan; 591(1):240-251. PubMed ID: 27878989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-Thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors of Bcl-2, Bcl-xL and Mcl-1.
    Song T; Li X; Chang X; Liang X; Zhao Y; Wu G; Xie S; Su P; Wu Z; Feng Y; Zhang Z
    Bioorg Med Chem; 2013 Jan; 21(1):11-20. PubMed ID: 23206987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.